FDA Approves New Treatments for Idiopathic Pulmonary Fibrosis and Eye Diseases

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-09
Category: health
Source: EMPR.COM (via Facebook)

The U.S. Food and Drug Administration (FDA) has approved Jascayd (nerandomilast) for the treatment of idiopathic pulmonary fibrosis. Additionally, Eydenzelt (aflibercept-boav) received approval as a biosimilar to Eylea, intended for certain eye diseases.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai